Cytomegalovirus infection in liver transplant recipients: Updates on clinical management

World Journal of Gastroenterology

Volumn 20, Issue 31, 2014, Pages 10658-10667

  Marcelin, Jasmine Riviere ^a   Beam, Elena ^a   Razonable, Raymund R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brincidofovir; Cytomegalovirus; Investigational; Letermovir; Liver transplantation; Prophylaxis; Resistance; Treatment; Valganciclovir

Indexed keywords

ALEMTUZUMAB; ARTESUNATE; BENZIMIDAVIR; BRINCIDOFOVIR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIGEN PP65; FOSCARNET; GANCICLOVIR; LEFLUNOMIDE; LETERMOVIR; VALGANCICLOVIR; ANTIVIRUS AGENT;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS INFECTION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LIVER GRAFT; META ANALYSIS (TOPIC); MIXED INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; ADVERSE EFFECTS; CYTOMEGALOVIRUS INFECTIONS; LIVER TRANSPLANTATION; PREDICTIVE VALUE; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; LIVER TRANSPLANTATION; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84909591974     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i31.10658     Document Type: Review

References (77)

1. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988-1994. Clin Infect Dis 2006; 43: 1143-1151 [PMID: 17029132 DOI: 10.1086/508173]
2. Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep 2012; 14: 633-641 [PMID: 22992839 DOI: 10.1007/s11908-012-0292-2]
3. Razonable RR. Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 2008; 14: 4849-4860 [PMID: 18756591]
4. Zhang LJ, Hanff P, Rutherford C, Churchill WH, Crumpacker CS. Detection of human cytomegalovirus DNA, RNA, and antibody in normal donor blood. J Infect Dis 1995; 171: 1002-1006 [PMID: 7706776]
5. Wohl DA, Kendall MA, Andersen J, Crumpacker C, Spector SA, Feinberg J, Alston-Smith B, Owens S, Chafey S, Marco M, Maxwell S, Lurain N, Jabs D, Benson C, Keiser P, Jacobson MA. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. HIV Clin Trials 2009; 10: 143-152 [PMID: 19632953 DOI: 10.1310/hct1003-143]
6. Limaye AP, Boeckh M. CMV in critically ill patients: pathogen or bystander? Rev Med Virol 2010; 20: 372-379 [PMID: 20931610 DOI: 10.1002/rmv.664]
7. Croen KD. Latency of the human herpesviruses. Annu Rev Med 1991; 42: 61-67 [PMID: 1852149 DOI: 10.1146/annurev.me.42.020191.000425]
8. Stratta RJ, Pietrangeli C, Baillie GM. Defining the risks for cytomegalovirus infection and disease after solid organ transplantation. Pharmacotherapy 2010; 30: 144-157 [PMID: 20099989 DOI: 10.1592/phco.30.2.144]
9. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62: S7-13 [PMID: 15821266]
10. George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, Med-Immune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113 [PMID: 9274893]
11. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097 [PMID: 11914998 DOI: 10.1086/339329]
12. Bansal N, Arora A, Kumaran V, Mehta N, Varma V, Sharma P, Tyagi P, Sachdeva M, Kumar A. Atypical Presentation of Cytomegalovirus Infection in a Liver Transplant Patient. J Clin Exp Hepatol 2011; 1: 207-209 [DOI: 10.1016/S0973-6883(11)60236-3]
13. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4: S78-S86 [PMID: 20070700 DOI: 10.1111/j.1600-6143.2009.02897.x]
14. Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K. Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients. J Clin Virol 2013; 57: 50-53 [PMID: 23403239 DOI: 10.1016/j.jcv.2013.01.013]
15. Arthurs SK, Eid AJ, Pedersen RA, Dierkhising RA, Kremers WK, Patel R, Razonable RR. Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007; 13: 1703-1709 [PMID: 18044717 DOI: 10.1002/lt.21280]
16. Linares L, Sanclemente G, Cervera C, Hoyo I, Cofán F, Ricart MJ, Pérez-Villa F, Navasa M, Marcos MA, Antón A, Pumarola T, Moreno A. Influence of cytomegalovirus disease in outcome of solid organ transplant patients. Transplant Proc 2011; 43: 2145-2148 [PMID: 21839217 DOI: 10.1016/j.transproceed.2011.05.007]
17. Montejo M, Montejo E, Gastaca M, Valdivieso A, Fernandez JR, Testillano M, Gonzalez J, Bustamante J, Ruiz P, Suarez MJ, Ventoso A, Rubio MC, de Urbina JO. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. Transplant Proc 2009; 41: 2189-2191 [PMID: 19715869 DOI: 10.1016/j.transproceed.2009.06.005]
18. Razonable RR. Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients. Infect Dis Clin North Am 2013; 27: 317-342 [PMID: 23714343 DOI: 10.1016/j.idc.2013.02.005]
19. Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol 2013; 85: 893-898 [PMID: 23508914 DOI: 10.1002/jmv.23539]
20. Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Perálvarez M, Rolando N, Harber M, Jones G, O'Riordan A, Burroughs AK, Thorburn D, O'Beirne J, Milne RS, Emery VC, Griffiths PD. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant 2012; 12: 2457-2464 [PMID: 22594993 DOI: 10.1111/j.1600-6143.2012.04087.x]
21. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013; 13 Suppl 4: 93-106 [PMID: 23465003 DOI: 10.1111/ajt.12103]
22. Manuel O, Kralidis G, Mueller NJ, Hirsch HH, Garzoni C, van Delden C, Berger C, Boggian K, Cusini A, Koller MT, Weisser M, Pascual M, Meylan PR. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402-2410 [PMID: 23914796 DOI: 10.1111/ajt.12388]
23. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48: 772-786 [PMID: 19207081 DOI: 10.1086/597089]
24. Sampaio AM, Guardia AC, Milan A, Sasaki AN, Andrade PD, Bonon SH, Stucchi RS, Botelho Costa SC, Boin IF. Coinfection and clinical impact of human herpesvirus 5 and 6 in liver transplantation. Transplant Proc 2012; 44: 2455-2458 [PMID: 23026619 DOI: 10.1016/j.transproceed.2012.07.034]
25. Katsolis JG, Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Gonwa TA, Hellinger WC. Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients. Transpl Infect Dis 2013; 15: 171-180 [PMID: 23331429 DOI: 10.1111/tid.12050]
26. Brown RA, Gralewski JH, Razonable RR. The R753Q polymorphism abrogates toll-like receptor 2 signaling in response to human cytomegalovirus. Clin Infect Dis 2009; 49: e96-e99 [PMID: 19814623 DOI: 10.1086/644501]
27. Kang SH, Abdel-Massih RC, Brown RA, Dierkhising RA, Kremers WK, Razonable RR. Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation. J Infect Dis 2012; 205: 639-646 [PMID: 22219347 DOI: 10.1093/infdis/jir819]
28. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360 [PMID: 23896556 DOI: 10.1097/TP.0b013e31829df29d]
29. Lisboa LF, Asberg A, Kumar D, Pang X, Hartmann A, Preiksaitis JK, Pescovitz MD, Rollag H, Jardine AG, Humar A. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011; 91: 231-236 [PMID: 21048530 DOI: 10.1097/TP.0b013e3181ff8719]
30. Marchetti S, Santangelo R, Manzara S, D'onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol 2011; 34: 157-164 [PMID: 21617827]
31. Martín-Gandul C, Pérez-Romero P, Sánchez M, Bernal G, Suárez G, Sobrino M, Merino L, Cisneros JM, Cordero E. Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection. J Clin Virol 2013; 56: 13-18 [PMID: 23131346 DOI: 10.1016/j.jcv.2012.09.017]
32. Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013; 56: 367-373 [PMID: 23097587 DOI: 10.1093/cid/cis900]
33. Fryer J, Heath AB, Anderson R, Minor PD; the Collaborative Study Group. Collaborative study to evaluate the proposed 1st [first] WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. Geneva: World Health Organization, 2010: 40
34. Hardie DR, Korsman SN, Hsiao NY. Cytomegalovirus load in whole blood is more reliable for predicting and assessing CMV disease than pp65 antigenaemia. J Virol Methods 2013; 193: 166-168 [PMID: 23792685 DOI: 10.1016/j.jviromet.2013.06.019]
35. Bodro M, Sabé N, Lladó L, Baliellas C, Niubó J, Castellote J, Fabregat J, Rafecas A, Carratalà J. Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients. Liver Transpl 2012; 18: 1093-1099 [PMID: 22532316 DOI: 10.1002/lt.23460]
36. Bosch W, Heckman MG, Diehl NN, Shalev JA, Pungpapong S, Hellinger WC. Association of cytomegalovirus infection and disease with death and graft loss after liver transplant in high-risk recipients. Am J Transplant 2011; 11: 2181-2189 [PMID: 21827609 DOI: 10.1111/j.1600-6143.2011.03618.x]
37. Onor IO, Todd SB, Meredith E, Perez SD, Mehta AK, Marshall Lyon G, Knechtle SJ, Hanish SI. Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transpl Int 2013; 26: 592-600 [PMID: 23590709 DOI: 10.1111/tri.12101]
38. Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant 2008; 8: 158-161 [PMID: 17973961 DOI: 10.1111/j.1600-6143.2007.02026.x]
39. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Pescovitz MD. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620 [PMID: 15023154 DOI: 10.1111/j.1600-6143.2004.00382.x]
40. Park JM, Lake KD, Arenas JD, Fontana RJ. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients. Liver Transpl 2006; 12: 112-116 [PMID: 16382458 DOI: 10.1002/lt.20562]
41. Brady RL, Green K, Frei C, Maxwell P. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients. Transpl Infect Dis 2009; 11: 106-111 [PMID: 19054381 DOI: 10.1111/j.1399-3062.2008.00356.x]
42. Fayek SA, Mantipisitkul W, Rasetto F, Munivenkatappa R, Barth RN, Philosophe B. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients. HPB (Oxford) 2010; 12: 657-663 [PMID: 21083790 DOI: 10.1111/j.1477-2574.2010.00226.x]
43. Kalil AC, Mindru C, Botha JF, Grant WJ, Mercer DF, Olivera MA, McCartan MA, McCashland TM, Langnas AN, Florescu DF. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis. Liver Transpl 2012; 18: 1440-1447 [PMID: 22887929 DOI: 10.1002/lt.23530]
44. Kalil AC, Mindru C, Florescu DF. Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis. Clin Infect Dis 2011; 52: 313-321 [PMID: 21189424 DOI: 10.1093/cid/ciq143]
45. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, Abramowicz D, Jardine AG, Voulgari AT, Ives J, Hauser IA, Peeters P. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237 [PMID: 20353469 DOI: 10.1111/j.1600-6143.2010.03074.x]
46. Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427-1431 [PMID: 21197713]
47. Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 2008; 8: 2111-2118 [PMID: 18828771 DOI: 10.1111/j.1600-6143.2008.02369.x]
48. Sun HY, Cacciarelli TV, Wagener MM, Singh N. Preemptive therapy for cytomegalovirus based on real-time measurement of viral load in liver transplant recipients. Transpl Immunol 2010; 23: 166-169 [PMID: 20609386 DOI: 10.1016/j.trim.2010.06.013]
49. University of Pittsburgh. Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in Liver Transplant Recipients ('CAPSIL' Study). In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000-2013. Available from: URL: http://clinicaltrials.gov/ct2/show/record/NCT01552369 NLM Identifier: NCT01552369
50. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, Pescovitz MD, Sgarabotto D, Tuncer M, Noronha IL, Hartmann A. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007; 7: 2106-2113 [PMID: 17640310 DOI: 10.1111/j.1600-6143.2007.01910.x]
51. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Snydman DR, Allen U, Humar A. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89: 779-795 [PMID: 20224515 DOI: 10.1097/TP.0b013e3181cee42f]
52. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, Mouas H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009; 9: 1205-1213 [PMID: 19422345 DOI: 10.1111/j.1600-6143.2009.02617.x]
53. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645-649 [PMID: 10968438 DOI: 10.1016/S0140-6736(00)02607-6]
54. Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010; 23: 689-712 [PMID: 20930070 DOI: 10.1128/CMR.00009-10]
55. Owers DS, Webster AC, Strippoli GF, Kable K, Hodson EM. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013; 2: CD005133 [PMID: 23450558]
56. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, Pescovitz MD, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, Freeman R, Heaton N, Covington E. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis 2004; 189: 1615-1618 [PMID: 15116297 DOI: 10.1086/382753]
57. Avery RK. Management of late, recurrent, and resistant cytomegalovirus in transplant patients. Trans Reviews 2007; 21: 65-76 [DOI: 10.1016/j.trre.2007.02.001]
58. Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR. Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 2007; 110: 490-500 [PMID: 17392502 DOI: 10.1182/blood-2007-01-069294]
59. Jacob CL, Lamorte L, Sepulveda E, Lorenz IC, Gauthier A, Franti M. Neutralizing antibodies are unable to inhibit direct viral cell-to-cell spread of human cytomegalovirus. Virology 2013; 444: 140-147 [PMID: 23849792 DOI: 10.1016/j.virol.2013.06.002]
60. Razonable RR. Immune-based therapies for cytomegalovirus infection. Immunotherapy 2010; 2: 117-130 [PMID: 20635892 DOI: 10.2217/imt.09.82]
61. Winston DJ, Saliba F, Blumberg E, Abouljoud M, Garcia-Diaz JB, Goss JA, Clough L, Avery R, Limaye AP, Ericzon BG, Navasa M, Troisi RI, Chen H, Villano SA, Uknis ME. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant 2012; 12: 3021-3030 [PMID: 22947426 DOI: 10.1111/j.1600-6143.2012.04231.x]
62. Marty FM, Boeckh M. Maribavir and human cytomegalovi-rus- what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 2011; 1: 555-562 [PMID: 22440913 DOI: 10.1016/j.coviro.2011.10.011]
63. Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 2010; 70: 965-981 [PMID: 20481654 DOI: 10.2165/10898540-000000000-00000]
64. Viro Pharma. Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients. In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000-2013. Available from: URL: http://clinicaltrials. gov/ct2/show/study/NCT01611974?term=maribavir&rank=1 NLM Identifier: NCT01611974
65. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol 2011; 85: 10884-10893 [PMID: 21752907 DOI: 10.1128/jvi.05265-11]
66. Marschall M, Stamminger T, Urban A, Wildum S, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 2012; 56: 1135-1137 [PMID: 22106211 DOI: 10.1128/aac.05908-11]
67. Lischka P, Hewlett G, Wunberg T, Baumeister J, Paulsen D, Goldner T, Ruebsamen-Schaeff H, Zimmermann H. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010; 54: 1290-1297 [PMID: 20047911 DOI: 10.1128/aac.01596-09]
68. James SH, Hartline CB, Harden EA, Driebe EM, Schupp JM, Engelthaler DM, Keim PS, Bowlin TL, Kern ER, Prichard MN. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother 2011; 55: 4682-4691 [PMID: 21788463 DOI: 10.1128/aac.00571-11]
69. Price NB, Prichard MN. Progress in the development of new therapies for herpesvirus infections. Curr Opin Virol 2011; 1: 548-554 [PMID: 22162744 DOI: 10.1016/j.coviro.2011.10.015]
70. Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol Blood Marrow Transplant 2012; 18: 731-738 [PMID: 21963623 DOI: 10.1016/j.bbmt.2011.09.007]
71. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broadspectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56: 2726-2734 [PMID: 22391537 DOI: 10.1128/aac.05983-11]
72. Papanicolau G, Kurtzberg J, Westervelt P, Gea-Banacloche J, Warlick E, Lanier R, Anderson M, Painter W. Experience With CMX001, a Novel Antiviral Drug, for Cytomegalovirus infections in Stem Cell Transplant Patients. Biol Blood Marrow Transplant 2011; 17: S273-S274
73. Marty FM, Winston D, Rowley SD, Boeckh M, Vance E, Papanicolaou G, Robertson A, Godkin S, Painter W. CMX001 for Prevention and Control of CMV Infection in CMV-Seropositive Allogeneic Stem-Cell Transplant Recipients: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Safety, Tolerability and Antiviral Activity. Biol Blood Marrow Transplant 2012; 18: S203-S204
74. Chimerix. A Study of the Safety and Efficacy for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R) Hematopoietic Stem Cell Transplant Recipients. Identifier: NCT01769170. In: ClinicalTrialsgov [Internet]. Bethesda (MD): National Library of Medicine (US), 2000-2013. Available from: URL: http://clinicaltrials.gov/ct2/show/study/NCT01769170?term=cmx001&rank=6 NLM
75. James SH, Price NB, Hartline CB, Lanier ER, Prichard MN. Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus. Antimicrob Agents Chemother 2013; 57: 3321-3325 [PMID: 23650158 DOI: 10.1128/aac.00062-13]
76. Griffiths P, Plotkin S, Mocarski E, Pass R, Schleiss M, Krause P, Bialek S. Desirability and feasibility of a vaccine against cytomegalovirus. Vaccine 2013; 31 Suppl 2: B197-B203 [PMID: 23598482 DOI: 10.1016/j.vaccine.2012.10.074]
77. Dasari V, Smith C, Khanna R. Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases. Expert Rev Vaccines 2013; 12: 661-676 [PMID: 23750795 DOI: 10.1586/erv.13.46]